liver cirrhosis/protease

Lyen an sove nan clipboard la

Chwazi kalite sòt

13 rezilta yo

HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. Introduction Hepatitis C infection is a major cause of chronic liver disease and death throughout the world1. Approximately 3% of the world's population is infected with hepatitis C virus (HCV)2. HCV is transmitted by blood and in the UK occurs primarily through injecting drug use. Chronically

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

With the advent of combined antiretroviral therapy (cART), patients infected with human immunodeficiency virus type 1 (HIV) are now living longer and dying of illnesses other than acquired immunodeficiency syndrome. Although outcome of liver transplantation (LT) in HIV and hepatitis C virus

Pilot HCV Direct Acting Antiviral Therapy and Metabolism

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

There is a heavy burden of metabolic disease in hepatitis C infected populations Allison et al (1994) were the first to identify an interaction between chronic hepatitis C virus (HCV) infection and diabetes, demonstrating an increase in the prevalence of type 2 diabetes among HCV-infected patients

Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chronic hepatitis C infection (CHC) is a major health problem, potentially leading to liver related mortality via complications of liver cirrhosis or hepatocellular carcinoma, and affects more than 185 million persons worldwide. Antiviral therapy evolved during the past 25 years from standard

Quantification of Side Effects During Hepatitis C Therapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatitis C Virus infection is one of the main causes of chronic liver disease worldwide with current estimates of approximately 130 - 210 million individuals (according to 3% of the world population) chronically infected with the hepatitis C virus. However, hepatitis C virus infections are among

Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Liver disease, especially viral hepatitis, is an important public health issue, which frequent leads to liver cirrhosis, hepatocellular carcinoma (HCC) and liver-related death. Around 340 to 400 million persons are infected with hepatitis B virus (HBV) and 130 to 210 million persons are infected

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In the last years, various clinical trials and studies have evaluated the incidence of hepatic toxicity (HT) associated with the commonly used antiretroviral drugs in the HIV/hepatitis C virus (HCV)-infected population. Unfortunately, clinical trials that compared hepatic safety of these

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 180 million people infected worldwide. In the US an estimated 4.1 million people are infected with HCV which is the principal cause of death from liver disease and leading indication for liver

Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

THISTLE - The HIV-HCV Silibinin Trial

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is frequent because of shared modes of viral transmission. Near 20% of HIV-infected patients are also infected with HCV, the prevalence of HCV in the HIV population varying according to the route of transmission.

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Primary Objective-To assess if switching from ritonavir boosted-PI based ART regimen to a Raltegravir-based regimen will reduce the rate of hepatic fibrosis progression in HIV-HCV co-infected patients as measured by transient elastography (Fibroscan®) and the AST-to-platelet ratio index (APRI) after

Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The prevalence of the HIV-HCV co-infection in Spain is one of the highest because both infections are strongly related to parenteral drugs use; so, from 61 to 69 % of HIV infected patients are also HCV infected. Acute HCV infection is asymptomatic in 60 to 70% of cases, being the chronification the

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye